^
    4d
    A Study of HS-20122 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=1050, Recruiting, Hansoh BioMedical R&D Company | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    5d
    A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=23, Active, not recruiting, Genmab | Recruiting --> Active, not recruiting | N=260 --> 23
    Enrollment closed • Enrollment change
    11d
    MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC (clinicaltrials.gov)
    P2, N=25, Not yet recruiting, Fujian Cancer Hospital
    New P2 trial
    |
    Tevimbra (tislelizumab-jsgr) • capecitabine • Meiyouheng (becotatug vedotin)
    11d
    A study protocol of a single-arm, prospective, open-label, non-controlled, phase II study of neoadjuvant BL-B01D1 combined with aumolertinib in resectable stage II-IIIB non-small cell lung cancer patients with EGFR mutation. (PubMed, Transl Lung Cancer Res)
    Registered on April 23, 2025. Protocol version: version 2.0, May 06, 2025.
    P2 data • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    Ameile (aumolertinib) • izalontamab brengitecan (BL-B01D1)
    13d
    Drug and single-cell gene expression integration identifies sensitive and resistant glioblastoma cell populations. (PubMed, Nat Commun)
    We validate the significance of these findings in vitro, ex vivo, and in vivo, and identify a combination of an OLIG2 inhibitor and Depatux-M for the treatment of GBM. Our studies suggest that scFOCAL identifies cell states that are sensitive and resistant to targeted therapies in GBM using a measure of cell and drug connectivity, which can be applied to identify new synergistic combinations.
    Journal
    |
    OLIG2 (Oligodendrocyte Transcription Factor 2)
    |
    depatuxizumab mafodotin (ABT-414)
    21d
    A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer (clinicaltrials.gov)
    P2, N=864, Not yet recruiting, Shanghai Junshi Bioscience Co., Ltd.
    New P2 trial
    |
    Loqtorzi (toripalimab-tpzi) • AWT020
    27d
    CA244-0001: A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=416, Recruiting, Bristol-Myers Squibb | N=238 --> 416 | Trial completion date: Aug 2028 --> Feb 2031 | Trial primary completion date: Dec 2026 --> Feb 2031
    Enrollment change • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tagrisso (osimertinib) • pumitamig (BNT327) • izalontamab (SI-B001) • izalontamab brengitecan (BL-B01D1)
    27d
    GenSci139-101: GenSci139 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=280, Recruiting, Changchun GeneScience Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    1m
    BL-B01D1-LUNG-101: Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors (clinicaltrials.gov)
    P1, N=470, Recruiting, SystImmune Inc. | N=260 --> 470 | Trial primary completion date: Dec 2025 --> Dec 2026
    Enrollment change • Trial primary completion date
    |
    izalontamab brengitecan (BL-B01D1)
    2ms
    Pembrolizumab + MRGOO3 as Neoadjuvant in NPC (clinicaltrials.gov)
    P2, N=35, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    New P2 trial
    |
    Keytruda (pembrolizumab) • Meiyouheng (becotatug vedotin)
    2ms
    A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=63, Recruiting, BeiGene | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    2ms
    A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, CSPC Megalith Biopharmaceutical Co.,Ltd.
    New P2 trial
    |
    cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed • SYS6010